PASCONAL NERVENTROPFEN in the Treatment of Nervous Diseases

PASCONAL NERVENTROPFEN in the Treatment of Adults and Children Suffering From Nervous Diseases (e.g. Sleep Disorders Due to Nervousness)

The purpose of this observational study is to give an overview of the use of PASCONAL NERVENTROPFEN in a 2-4 week treatment of nervous diseases, especially sleep disorders due to nervousness.

The purpose of this observational study is to give an overview of the use of PASCONAL NERVENTROPFEN in a 2-4 week treatment of nervous diseases, especially sleep disorders due to nervousness.

Efficacy and tolerability of the drug will be assessed. Special regard will be taken to the administration management, dose regimen, and to the effectiveness and safety in special patient groups (children 1-12 years of age), in relation to treatment conformity to the Summary of Product Characteristics (SmPC).

Due to the design as an Observational Study no inclusion or exclusion criteria for therapy are named. The included patient group is described under "Cohort / Group".

Observational Criteria (=inclusion criteria for documentation):

• Males and females
• Children 1-12 years old
• Adults >12 years old
• suffering from nervous diseases, e.g. sleep disorders due to nervousness.

Exclusion criteria for documentation:

• children younger than 1 year
• no nervous diseases, e.g. sleep disorders due to nervousness.
• no treatment with PASCONAL NERVENTROPFEN